Zenith Drugs Ltd.
NNSE:ZENITHDRUG38.20
INR
0.00
(0.00%)
ISIN
INE0QWN01013
Return %
Stock
S&P 500
1Y
-38.44
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Sandeep Bhardwaj
- Full Time Employees
- 172
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Scheme No. 134 Indore MP India 452010
- IPO Date
- Feb 27, 2024
- Website
- zenithdrugs.com
- Similar Companies
- Business
- Zenith Drugs Ltd (NSE: ZENITHDRUG) manufactures and trades pharmaceutical formulations, specializing in branded generics, generics, and over-the-counter (OTC) products including oral rehydration salts (ORS) powder; liquid orals; ointments, creams, gels, and liquid externals; capsules; tablets; and dry powders. The company operates a WHO-GMP and ISO-certified state-of-the-art manufacturing facility in Indore, Madhya Pradesh, producing over 250 molecules and 780 SKUs across dedicated lines for these categories, serving healthcare practitioners, institutions, and government tenders. Zenith Drugs supplies trusted partners such as Ajanta Pharma, Micro Labs, May & Baker, and Kopran, while excelling as one of Central India's largest ORS sachet manufacturers. Established in 2000 and headquartered at 75/1/1 Muradpura (Orangpura), Dhar Road, near Kalariya, Indore, Madhya Pradesh 453001, India, the company maintains a strong domestic presence across 18 Indian states—with Madhya Pradesh contributing 24% of revenue—and pursues international expansion into West and East Africa, Southeast Asia, and Latin America. Through wholly owned subsidiaries Biozen Healthcare and Biogenesis Corporation, Zenith Drugs markets branded generics, conducts third-party manufacturing, and handles government/institutional business and exports via merchant dealers. The firm emphasizes research and development in therapeutic areas including allergology, general analgesics, infections, genetics, endocrinology, and microbiology. In recent developments, Zenith Drugs converted to a public limited company in 2023 ahead of its initial public offering (IPO) on the National Stock Exchange of India in February 2024, utilizing proceeds for new unit machinery, manufacturing block upgradation, working capital, and general corporate purposes. The company achieved annual turnover of INR 131.62 crore in 2024, up from INR 114.5 crore in 2023, with expectations to exceed INR 175 crore in 2025 amid ongoing revenue growth and product portfolio diversification. It plans to launch a new product line and continues institutional supply growth under robust compliance leadership.